In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA ODE IV reorganization gives H. pylori reviews to new Division of Special Pathogens & Immunologic Drugs.

Executive Summary

FDA H. PYLORI THERAPY REVIEWS ASSIGNED TO DIVISION OF SPECIAL PATHOGENS and Immunologic Drug Products under a reorganization of the Office of Drug Evaluation IV. The new review division (HFD-590) was created to assume some of the workload of the Divisions of Anti-Infective Drug Products and Anti-Viral Drug Products May 12. Drug categories to be reviewed by the immunologic drugs division include drugs for non-viral opportunistic infections in AIDS patients, anti-mycobacterial drugs, solid organ transplant drugs, systemic anti-fungals including liposomal amphotericin products, vaginal anti-fungals, quinolone antibiotics not intended for ear/nose/throat indications, anti-parasitics, treatments for Helicobacter pylori, vaginal products for HIV and immunomodulating drugs, including some indications of thalidomide.
UsernamePublicRestriction

Register

PS030244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel